Provided by Tiger Trade Technology Pte. Ltd.

First Trust Nasdaq Pharmaceuticals ETF

41.25
-0.0200-0.05%
Post-market: 41.250.00000.00%16:10 EDT
Volume:25.39K
Turnover:1.05M
Market Cap:1.06B
PE:- -
High:41.51
Open:41.37
Low:41.18
Close:41.27
52wk High:43.52
52wk Low:28.77
Shares:25.80M
Float Shares:25.80M
Volume Ratio:0.08
T/O Rate:0.10%
Dividend:0.29
Dividend Rate:0.70%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Bristol-Myers Squibb Company - Phase 3 Action-1 Study Meets Primary Endpoint with Improved Progression-Free Survival

THOMSON REUTERS
·
Yesterday

Bristol Myers' Lung Disease Drug Meets Main Goal in Late-Stage Trial

Reuters
·
Yesterday

Street View: Merck Eye Disease Drug Matches Roche's Therapy in Study, Analysts Cautious

Reuters
·
Yesterday

Bristol Myers Squibb Says Phase 3 ALOFT-IPF Trial Shows Admilparant 60 Mg Meets Primary Endpoint

Reuters
·
Yesterday

Bristol-Myers Squibb Company - Admilparant Demonstrates Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
Yesterday

Bristol-Myers Squibb Company - Admilparant Phase 3 Aloft-Ppf Trial Topline Results Expected Early 2027

THOMSON REUTERS
·
Yesterday

Bristol-Myers Squibb Company - Admilparant 120 Mg Dose Slowed Fvc Decline but not Statistically Significant

THOMSON REUTERS
·
Yesterday

Bristol Myers Squibb Announces Phase 3 Aloft-Ipf Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

THOMSON REUTERS
·
Yesterday

Citigroup Adjusts Price Target on Merck & Co. to $145 From $125

MT Newswires Live
·
Yesterday

Merck & Co Inc : RBC Cuts Target Price to $145 from $150

THOMSON REUTERS
·
Yesterday

Analysts Are Bullish on These Healthcare Stocks: Merck & Company (MRK), Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Yesterday

Eli Lilly & Co (LLY) Receives a Buy from Barclays

TIPRANKS
·
Yesterday

Merck announces one-year results from Phase 2b/3 Brunello trial

TIPRANKS
·
Yesterday

AbbVie Says Phase 3 Affirm Study Shows Subcutaneous Skyrizi Beats Placebo on Crohn’s Remission, Endoscopic Response at Week 12

Reuters
·
Yesterday

Eli Lilly (LLY) Reported Broader Biomarker Effects In Phase 3b Psoriasis Trial

Simply Wall St.
·
Oct 11

Merck Says Remigromig Meets Primary Endpoint in Brunello Diabetic Macular Edema Trial at One Year

Reuters
·
Oct 11

Merck Presents One-Year Results from the Pivotal Phase 2B/3 Brunello Study Evaluating Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at Aao 2026

THOMSON REUTERS
·
Oct 11

Merck & Co - Remigromig Demonstrates Non-Inferior Visual Acuity Versus Ranibizumab at One Year in Dme

THOMSON REUTERS
·
Oct 11

Johnson & Johnson (JNJ) Faces Fresh Patent Lawsuit Over Cardiology Device

Simply Wall St.
·
Oct 10

AbbVie Inc. Stock Underperforms Friday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Oct 10